Philogen

Index
Globenewswire

Nidlegy™ Phase III PIVOTAL Trial Meets the Study’s Primary Objective Demonstrating Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival for Patients with Locally Advanced Fully Resectable Melanoma